Docetaxel/trastuzumab regime: Uses in HER2-positive early breast cancer

被引：0
|
作者：
Arnheim, Katharina
机构：
来源：
BREAST CARE | 2006年 / 1卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：A1 / A4
页数：4
相关论文
共 50 条
  • [1] Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
    Swain, Sandra M.
    Baselga, Jose
    Kim, Sung-Bae
    Ro, Jungsil
    Semiglazov, Vladimir
    Campone, Mario
    Ciruelos, Eva
    Ferrero, Jean-Marc
    Schneeweiss, Andreas
    Heeson, Sarah
    Clark, Emma
    Ross, Graham
    Benyunes, Mark C.
    Cortes, Javier
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (08): : 724 - 734
  • [2] Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer
    Kawajiri, Hidemi
    Takashima, Tsutomu
    Kashiwagi, Shinichiro
    Noda, Satoru
    Onoda, Naoyoshi
    Hirakawa, Kosei
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (01) : 17 - 26
  • [3] Neoadjuvant chemotherapy with docetaxel, carboplatin and biosimilar trastuzumab in Her2-positive early breast cancer.
    Oukkal, Mohammed
    Challal, Souad
    Benmelha, Nawel Abed
    Benachenhou, Nabil
    Boubnider, Mohcen Wahib
    Kouchkar, Amal
    Terki, Nadia
    Benkhedda, Ghania
    Brahimi, Ghania
    Belkaid, Roza
    Bouzid, Kamel
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Docetaxel/trastuzumab improves disease-free survival in early HER2-positive breast cancer
    不详
    ONCOLOGY-NEW YORK, 2006, 20 (05): : 475 - 475
  • [5] Trastuzumab and Vinorelbine in Early Stages of HER2-Positive Breast Cancer
    Ferrario, C.
    Wong, A.
    Gao, T.
    Bouganim, N.
    Aloyz, R.
    Panasci, L. C.
    JOURNAL OF CHEMOTHERAPY, 2011, 23 (01) : 32 - 35
  • [6] Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
    von Minckwitz, Gunter
    Procter, Marion
    de Azambuja, Evandro
    Zardavas, Dimitrios
    Benyunes, Mark
    Viale, Giuseppe
    Suter, Thomas
    Arahmani, Amal
    Rouchet, Nathalie
    Clark, Emma
    Knott, Adam
    Lang, Istvan
    Levy, Christelle
    Yardley, Denise A.
    Bines, Jose
    Gelber, Richard D.
    Piccart, Martine
    Baselga, Jose
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (02): : 122 - 131
  • [7] Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer
    Douchet, G.
    Richard, Sandrine
    ONCOLOGIE, 2018, 20 (01) : 43 - 44
  • [8] Optimal duration of trastuzumab for early HER2-positive breast cancer
    Specht, Jennifer M.
    Davidson, Nancy E.
    LANCET, 2017, 389 (10075): : 1167 - 1168
  • [9] Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer
    Vieira, Claudia
    Borges, Andreia
    Pereira, Filipa F.
    Antunes, Pedro
    Redondo, Patricia
    Antunes, Luis
    Lopes, Jose M.
    Goncalves, Francisco R.
    Borges, Marina
    Bento, Maria J.
    JOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY, 2023, 6 (01) : 1 - 9
  • [10] Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer
    Isabel Echavarria
    Mónica Granja
    Coralia Bueno
    Sara Lopez-Tarruella
    Paloma Peinado
    Miguel Sotelo
    Yolanda Jerez
    Fernando Moreno
    Gabriela Torres
    Miriam Lobo
    Ivan Marquez-Rodas
    Maria Del Monte-Millan
    Miguel Martín
    Jose Angel García-Saenz
    Breast Cancer Research and Treatment, 2017, 162 : 181 - 189
12345